EMAIL THIS PAGE TO A FRIEND

Expert opinion on investigational drugs

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.


PMID 18616418

Abstract

Glioblastoma multiforme (GBM), a highly invasive and vascular cancer, responds poorly to conventional cytotoxic therapy. Integrins, widely expressed in GBM and tumor vasculature, mediate cell survival, migration and angiogenesis. Cilengitide is a potent alphavbeta3 and alphavbeta5 integrin inhibitor. To summarize the preclinical and clinical experience with cilengitide for GBM. Preclinical studies and clinical trials evaluating cilengitide for GBM were reviewed. Cilengitide is active and synergizes with external beam radiotherapy in preclinical GBM models. In clinical trials for recurrent GBM, single-agent cilengitide has antitumor benefits and minimal toxicity. Among newly diagnosed GBM patients, single-arm studies incorporating cilengitide into standard external beam radiotherapy/temozolomide have shown encouraging activity with no increased toxicity and have led to a planned randomized Phase III trial.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SML1594 Cilengitide trifluoroacetic acid salt, ≥98% (HPLC)
C27H40N8O7 · xC2HF3O2